Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials | NOVA. The University of Newcastle's Digital Repository
暂无分享,去创建一个
P. Sandercock | J. Grotta | M. Kaste | W. Hacke | G. Donnan | J. Wardlaw | B. Tilley | T. Brott | J. Emberson | C. Baigent | J. Olivot | G. Albers | M. Lansberg | G. Howard | L. Blackwell | S. Davis | G. Murray | M. Parsons | K. Lees | R. Lindley | G. D. del Zoppo | E. Bluhmki | N. Wahlgren | D. Toni | P. Lyden | M. Koga | K. Toyoda | W. Whiteley | Geoff Cohen | G. Donnan | R. von Kummer | G. Zoppo | R. Kummer | G. Albers | G. D. Murray | G. Cohen | Stephen M. Davis | S. Davis | W. Hacke
[1] K. Lees,et al. The Effect of Time to Treatment on Outcome in Very Elderly Thrombolysed Stroke Patients , 2013, International journal of stroke : official journal of the International Stroke Society.
[2] E. Mori,et al. Guidelines for the intravenous application of recombinant tissue-type plasminogen activator (alteplase), the second edition, October 2012: a guideline from the Japan Stroke Society. , 2013, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.
[3] P. Sandercock,et al. Details of a prospective protocol for a collaborative meta-analysis of individual participant data from all randomized trials of intravenous rt-PA vs. control: statistical analysis plan for the Stroke Thrombolysis Trialists' Collaborative meta-analysis , 2013, International Journal of Stroke.
[4] George Howard,et al. Population shifts and the future of stroke: forecasts of the future burden of stroke , 2012, Annals of the New York Academy of Sciences.
[5] Geoff Cohen,et al. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial , 2012, The Lancet.
[6] Geoff Cohen,et al. Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis , 2012, The Lancet.
[8] H. Diener,et al. Influence of Age on Outcome From Thrombolysis in Acute Stroke: A Controlled Comparison in Patients From the Virtual International Stroke Trials Archive (VISTA) , 2010, Stroke.
[9] K. Lees,et al. Thrombolysis in very elderly people: controlled comparison of SITS International Stroke Thrombolysis Registry and Virtual International Stroke Trials Archive , 2010, BMJ : British Medical Journal.
[10] Elsa Azevedo,et al. Intravenous Alteplase for Stroke in Those Older Than 80 Years Old , 2010, Stroke.
[11] J. Grotta,et al. Intravenous Thrombolysis Plus Hypothermia for Acute Treatment of Ischemic Stroke (ICTuS-L): Final Results , 2010, Stroke.
[12] Gregory W Albers,et al. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials , 2010, The Lancet.
[13] Tammy Hoffmann,et al. Clinical Guidelines for Stroke Management 2010 , 2010 .
[14] M. Kaste,et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. , 2008, The New England journal of medicine.
[15] Gary A. Ford,et al. Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. , 2008, Cerebrovascular diseases.
[16] Keith Muir,et al. Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a placebo-controlled randomised trial , 2008, The Lancet Neurology.
[17] Werner Hacke,et al. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study , 2007, The Lancet.
[18] Scott Hamilton,et al. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials , 2004, The Lancet.
[19] Nan Hu,et al. [Early intravenous thrombolysis with recombinant tissue plasminogen activator for acute cerebral infarction]. , 2003, Zhongguo wei zhong bing ji jiu yi xue = Chinese critical care medicine = Zhongguo weizhongbing jijiuyixue.
[20] J Carpenter,et al. Bootstrap confidence intervals: when, which, what? A practical guide for medical statisticians. , 2000, Statistics in medicine.
[21] G. Albers,et al. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. , 1999, JAMA.
[22] M. Kaste,et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II) , 1998, The Lancet.
[23] T. N. t-P. S. S. Group,et al. Generalized efficacy of t-PA for acute stroke. Subgroup analysis of the NINDS t-PA Stroke Trial. , 1997, Stroke.
[24] Koroshetz Wj,et al. Tissue plasminogen activator for acute ischemic stroke. , 1996, The New England journal of medicine.
[25] Joseph P. Broderick,et al. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. , 1995 .
[26] M. Kaste,et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS) , 1995, JAMA.
[27] J. Broderick,et al. Pilot Randomized Trial of Tissue Plasminogen Activator in Acute Ischemic Stroke , 1993 .
[28] J. Broderick,et al. Pilot randomized trial of tissue plasminogen activator in acute ischemic stroke. The TPA Bridging Study Group. , 1993, Stroke.
[29] T. Hayakawa,et al. Intravenous Tissue Plasminogen Activator Ameliorates the Outcome of Hyperacute Embolic Stroke , 1993 .
[30] A. Yamadori,et al. Intravenous recombinant tissue plasminogen activator in acute carotid artery territory stroke , 1992, Neurology.
[31] David A. Schoenfeld,et al. Partial residuals for the proportional hazards regression model , 1982 .